Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Prostate Cancer Prostatic Dis
; 12(1): 100-3, 2009.
Article
en En
| MEDLINE
| ID: mdl-18574491
We present a case report of a patient with prostate cancer who failed to demonstrate consistent testosterone suppression to castration levels and incomplete suppression of serum prostate-specific antigen, although treated with gonadotropin releasing hormone agonists for 48 months. Serum dehydroepiandrosterone, dehydroepiandrosterone sulphate, as well as the androgen metabolite, androsterone glucuronide, were elevated compared to the other patients. The present data suggest that those prostate cancer patients who have even marginally elevated adrenal androgens may especially benefit from combined androgen blockade.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Adenocarcinoma
/
Hormona Liberadora de Gonadotropina
/
Andrógenos
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Prostate Cancer Prostatic Dis
Asunto de la revista:
ENDOCRINOLOGIA
/
NEOPLASIAS
/
UROLOGIA
Año:
2009
Tipo del documento:
Article
País de afiliación:
Israel
Pais de publicación:
Reino Unido